TY - JOUR
T1 - LOCUS (LOng Covid–Understanding Symptoms, events and use of services in Portugal)
T2 - a three-component study protocol
AU - Dinis Teixeira, J. P.
AU - Santos, Mário J.D.S.
AU - Soares, Patrícia
AU - Azevedo, Luísa de
AU - Barbosa, Patrícia
AU - Boas, Andreia Vilas
AU - Cordeiro, João V.
AU - Dias, Sónia
AU - Fonseca, Marta
AU - Goes, Ana Rita
AU - Lobão, Maria João
AU - Moniz, Marta
AU - Nóbrega, Sofia
AU - Peralta-Santos, André
AU - Ramos, Víctor
AU - Rocha, João Victor
AU - Silva, António Carlos da
AU - da Luz Brazão, Maria
AU - Leite, Andreia
AU - Nunes, Carla
N1 - Publisher Copyright:
© 2023 Dinis Teixeira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023/4
Y1 - 2023/4
N2 - Approximately 10% of patients experience symptoms of Post COVID-19 Condition (PCC) after a SARS-CoV-2 infection. Akin acute COVID-19, PCC may impact a multitude of organs and systems, such as the cardiovascular, respiratory, musculoskeletal, and neurological systems. The frequency and associated risk factors of PCC are still unclear among both community and hospital settings in individuals with a history of COVID-19. The LOCUS study was designed to clarify the PCC’s burden and associated risk factors. LOCUS is a multi-component study that encompasses three complementary building blocks. The “Cardiovascular and respiratory events following COVID-19” component is set to estimate the incidence of cardiovascular and respiratory events after COVID-19 in eight Portuguese hospitals via electronic health records consultation. The “Physical and mental symptoms following COVID-19” component aims to address the community prevalence of self-reported PCC symptoms through a questionnaire-based approach. Finally, the "Treating and living with Post COVID-19 Condition" component will employ semi-structured interviews and focus groups to characterise reported experiences of using or working in healthcare and community services for the treatment of PCC symptoms. This multi-component study represents an innovative approach to exploring the health consequences of PCC. Its results are expected to provide a key contribution to the optimisation of healthcare services design.
AB - Approximately 10% of patients experience symptoms of Post COVID-19 Condition (PCC) after a SARS-CoV-2 infection. Akin acute COVID-19, PCC may impact a multitude of organs and systems, such as the cardiovascular, respiratory, musculoskeletal, and neurological systems. The frequency and associated risk factors of PCC are still unclear among both community and hospital settings in individuals with a history of COVID-19. The LOCUS study was designed to clarify the PCC’s burden and associated risk factors. LOCUS is a multi-component study that encompasses three complementary building blocks. The “Cardiovascular and respiratory events following COVID-19” component is set to estimate the incidence of cardiovascular and respiratory events after COVID-19 in eight Portuguese hospitals via electronic health records consultation. The “Physical and mental symptoms following COVID-19” component aims to address the community prevalence of self-reported PCC symptoms through a questionnaire-based approach. Finally, the "Treating and living with Post COVID-19 Condition" component will employ semi-structured interviews and focus groups to characterise reported experiences of using or working in healthcare and community services for the treatment of PCC symptoms. This multi-component study represents an innovative approach to exploring the health consequences of PCC. Its results are expected to provide a key contribution to the optimisation of healthcare services design.
UR - http://www.scopus.com/inward/record.url?scp=85153980698&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0285051
DO - 10.1371/journal.pone.0285051
M3 - Article
C2 - 37099589
AN - SCOPUS:85153980698
SN - 1932-6203
VL - 18
JO - PLoS ONE
JF - PLoS ONE
IS - 4
M1 - e0285051
ER -